Javascript must be enabled to continue!
Abstract 1624: Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells.
View through CrossRef
Abstract
In addition to serving crucial roles in bone development, Hedgehog (Hh) signaling contributes to the development and progression of many cancers, making it an attractive candidate for treatment of bone-resident cancers. Recent data suggest that Hh-targeted agents exert pluripotent effects on host bone microenvironment cells through both cell-intrinsic and paracrine mechanisms, interrupting the ‘vicious cycle’ of tumor cell, osteoblast (OB), osteoclast (OC), and bone marrow stromal cell (BMSC) interactions in bone metastatic breast cancers. Here, reciprocal stimulation between tumor cells and bone cells enhance both tumor growth and bone pathology. Similarly, development of osteosarcoma (OS), the most common primary bone cancer, is strongly influenced by conditions within surrounding microenvironment providing additional points for therapeutic intervention.
The 5-year survival rate for metastatic OS is under 30%, highlighting the need for novel and targeted treatments. We have demonstrated that mice deficient in the tumor suppressor ARF (p19ARF; p14ARF in humans) have enhanced rates of bone turnover, mimicking the adolescent growth period in which OS is prevalent. By crossing Arf-/- mice with those expressing Tax, an HTLV-1 oncogene that results in osteolytic tumors, we developed a model of high penetrant spontaneous OS that recapitulates many aspects of human disease. Here, suppression of bone turnover with the bisphosphonate zoledronic acid prevented the development of OS, suggesting that enhanced OC activity may stimulate OS growth. In agreement, we found that Tax+Arf-/- OS had increased RANKL-to-OPG ratios resulting in increased osteoclastogenic ability. Compared to normal osteoblasts and mesenchymal stem cell precursors, Tax+Arf-/- OS cells have increased expression of Hh pathway genes and exhibit increased susceptibility to Hh inhibitors (SMO antagonists). In particular, Tax+Arf-/- OS cells express high levels of the Hh ligands Sonic (SHH) and Indian (IHH), suggesting they may stimulate surrounding cells in a paracrine fashion. Notably, BMSC derived from non-tumor bearing Tax+Arf-/- mice also exhibit increased expression of pro-tumorigenic factors (including IL-6 and IGF), generating a fertile ‘soil’. SHH or conditioned media from Tax+Arf-/- OS cells enhanced OC activity and BMSC cell production of pro-tumorigenic growth factors. Furthermore, the increased OB and OC differentiation and activity present in Tax+Arf-/- cells could be abrogated with SMO inhibitors. We have established an OS cell line from Tax+Arf-/- mice (TAN) with the ability to form mineralized tumors upon intratibial injection. Using this model, we hypothesize that treatment with SMO antagonists will decrease OS growth due to both tumor cytotoxic effects and direct effects on host bone microenvironment cells that abrogate the pro-tumor microenvironment.
Citation Format: Michelle Anne Hurchla, Katherine N. Weilbaecher. Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1624. doi:10.1158/1538-7445.AM2013-1624
American Association for Cancer Research (AACR)
Title: Abstract 1624: Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells.
Description:
Abstract
In addition to serving crucial roles in bone development, Hedgehog (Hh) signaling contributes to the development and progression of many cancers, making it an attractive candidate for treatment of bone-resident cancers.
Recent data suggest that Hh-targeted agents exert pluripotent effects on host bone microenvironment cells through both cell-intrinsic and paracrine mechanisms, interrupting the ‘vicious cycle’ of tumor cell, osteoblast (OB), osteoclast (OC), and bone marrow stromal cell (BMSC) interactions in bone metastatic breast cancers.
Here, reciprocal stimulation between tumor cells and bone cells enhance both tumor growth and bone pathology.
Similarly, development of osteosarcoma (OS), the most common primary bone cancer, is strongly influenced by conditions within surrounding microenvironment providing additional points for therapeutic intervention.
The 5-year survival rate for metastatic OS is under 30%, highlighting the need for novel and targeted treatments.
We have demonstrated that mice deficient in the tumor suppressor ARF (p19ARF; p14ARF in humans) have enhanced rates of bone turnover, mimicking the adolescent growth period in which OS is prevalent.
By crossing Arf-/- mice with those expressing Tax, an HTLV-1 oncogene that results in osteolytic tumors, we developed a model of high penetrant spontaneous OS that recapitulates many aspects of human disease.
Here, suppression of bone turnover with the bisphosphonate zoledronic acid prevented the development of OS, suggesting that enhanced OC activity may stimulate OS growth.
In agreement, we found that Tax+Arf-/- OS had increased RANKL-to-OPG ratios resulting in increased osteoclastogenic ability.
Compared to normal osteoblasts and mesenchymal stem cell precursors, Tax+Arf-/- OS cells have increased expression of Hh pathway genes and exhibit increased susceptibility to Hh inhibitors (SMO antagonists).
In particular, Tax+Arf-/- OS cells express high levels of the Hh ligands Sonic (SHH) and Indian (IHH), suggesting they may stimulate surrounding cells in a paracrine fashion.
Notably, BMSC derived from non-tumor bearing Tax+Arf-/- mice also exhibit increased expression of pro-tumorigenic factors (including IL-6 and IGF), generating a fertile ‘soil’.
SHH or conditioned media from Tax+Arf-/- OS cells enhanced OC activity and BMSC cell production of pro-tumorigenic growth factors.
Furthermore, the increased OB and OC differentiation and activity present in Tax+Arf-/- cells could be abrogated with SMO inhibitors.
We have established an OS cell line from Tax+Arf-/- mice (TAN) with the ability to form mineralized tumors upon intratibial injection.
Using this model, we hypothesize that treatment with SMO antagonists will decrease OS growth due to both tumor cytotoxic effects and direct effects on host bone microenvironment cells that abrogate the pro-tumor microenvironment.
Citation Format: Michelle Anne Hurchla, Katherine N.
Weilbaecher.
Targeting the Hedgehog pathway to inhibit osteosarcoma growth through dual effects on tumor and microenvironment cells.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1624.
doi:10.
1158/1538-7445.
AM2013-1624.
Related Results
Riluzole as a Dual-Targeted Radiosensitizer for Osteosarcoma: Targeting Tumor Cells and Angiogenic Vasculature to Enhance Single High Dose Radiotherapy Efficacy
Riluzole as a Dual-Targeted Radiosensitizer for Osteosarcoma: Targeting Tumor Cells and Angiogenic Vasculature to Enhance Single High Dose Radiotherapy Efficacy
Abstract
Osteosarcoma is a highly aggressive bone malignancy primarily affecting children and young adults. It presents significant treatment challenges due to its inhe...
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract
Osteosarcoma is the most common primary tumor of bones. In the past three decades treatment paradigms and survival rates have not improved. While osteosarco...
Hedgehog Signaling and Embryonic Craniofacial Disorders
Hedgehog Signaling and Embryonic Craniofacial Disorders
Since its initial discovery in a Drosophila mutagenesis screen, the Hedgehog pathway has been revealed to be instrumental in the proper development of the vertebrate face. Vertebra...
Abstract 1637: GPX4-mediated Pathway Regulates Iron Efflux to Prevent Ferroptotic Cell Death and Promote Immunosuppressive Signals in Osteosarcoma Cells
Abstract 1637: GPX4-mediated Pathway Regulates Iron Efflux to Prevent Ferroptotic Cell Death and Promote Immunosuppressive Signals in Osteosarcoma Cells
Abstract
Osteosarcoma is a malignant bone sarcoma prevalent in children, adolescents, and young adults, with limited treatment options. Targeting ferroptosis, an iro...
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract
Osteosarcoma, the primary malignant tumor of bone, is the most frequent primary non-hematologic malignancy in children and adolescents. Despite the advances...
Identification and validation of the important role of YAP in the development and progression of Osteosarcoma
Identification and validation of the important role of YAP in the development and progression of Osteosarcoma
Abstract
Aim
This study aims to explore the molecular mechanisms of osteosarcoma by integrating multi-omics data to identify key genes and pathways, with a focus on the Hi...
Conjugate vaccines targeting the tumor vasculature
Conjugate vaccines targeting the tumor vasculature
Cancer cells acquire critical hallmarks which eventually facilitate the formation of malignant tumors. In this thesis, we highlighted two important hallmarks, the induction of angi...
GLS1 Promotes The Malignant Progression of Osteosarcoma
GLS1 Promotes The Malignant Progression of Osteosarcoma
Abstract
Background: Osteosarcoma (OS) is the most frequent and high-grade young malignant bone tumor. The prognosis is still poor despite the use of combined therapy invol...

